Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Breast Recontruction

• Status: Withdrawn
• Trial end date: 2020-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine the most effective way to control post-operative breast pain for patients undergoing a unilateral, immediate breast reconstruction.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Case Comprehensive Cancer Center
• Treatments: Bupivacaine; Narcotics

Criteria

Inclusion Criteria:

• Patients scheduled to have a unilateral, immediate breast reconstruction

Exclusion Criteria:

• Pregnant

• Concurrent or recent medical condition that could interfere with study participation including:

• Hepatitis

• Alcohol/substance abuse

• Uncontrolled psychiatric disorders

• Known allergy

• Contraindication to amide-type local anesthetics, opioids, or propofol.

• Body weight of less than 50 kg

• Participated in another study involving an investigational medication within the prior 30 days

• Taking analgesics (i.e., nonsteroidal anti-inflammatory drugs, acetaminophen, or opioids), antidepressants, or glucocorticoids within the 3 days before surgery.